Format

Send to

Choose Destination
See comment in PubMed Commons below
Sci Transl Med. 2012 Feb 22;4(122):122cm3. doi: 10.1126/scitranslmed.3003490.

Recalibrating intellectual property rights to enhance translational research collaborations.

Author information

1
Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton Clinic Health Academy, 11405 87 Avenue, Edmonton, Alberta, T6G 1C9, Canada. tbubela@ualberta.ca

Abstract

Multisectoral collaborative models for drug and therapeutic research and development (R&D) are emerging, requiring a recalibration of how intellectual property rights (IPRs) are used. Although these models appear promising, little study has been conducted on the optimal blend of sharing and exclusion as mediated through the proactive use or nonuse of IPRs. This Commentary is a call for a combination of theoretical and empirical analyses to build a comprehensive understanding of the interplay between formal IP laws, institutions that administer and manage IPRs, and the use of IPRs in practice to better construct and manage collaborations. Such analyses require outcome metrics formulated to measure the success of therapeutic outcomes and to capture the complexity of a highly networked R&D environment.

PMID:
22357536
DOI:
10.1126/scitranslmed.3003490
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center